ResMed | RMD - Gross Profit On Sales

Stock Price
204.15
Daily Change
2.27 1.12%
Monthly
-9.72%
Yearly
-19.42%
Q2 Forecast
197.82

ResMed reported $890.98M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Ansell USD 326.2M 27.6M Jun/2024
Artivion USD 73.14M 1.25M Dec/2025
AtriCure USD 109.31M 3.97M Mar/2026
Baxter International USD 891M 314M Mar/2026
Cochlear AUD 856.8M 430M Dec/2025
Cooper Companies USD 695.2M 44.4M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Dexcom USD 750.3M 42.4M Mar/2026
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
Fisher Paykel Healthcare NZD 685.7M 3.5M Dec/2025
Globus Medical USD 496.26M 39.69M Mar/2026
Haemonetics USD 202.39M 7.64M Dec/2025
Idexx Laboratories USD 722.74M 64.62M Mar/2026
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 540.8M 27.8M Mar/2026
Integra LifeSciences USD 213.21M 3.89M Mar/2026
Intuitive Surgical USD 1.83B 73.8M Mar/2026
Masimo USD 250.8M 3.5M Mar/2026
Medtronic USD 5.41B 27M Dec/2025
Philips EUR 1.77B 522M Mar/2026
Ramsay Health Care AUD 549.95M 5.77B Jun/2025
ResMed USD 890.98M 12.26M Mar/2026
Sigma Healthcare AUD 160.13M 10.55M Jul/2024
Sonic Healthcare AUD 3.92B 3.14B Dec/2024
Steris USD 655.5M 9.6M Dec/2025
Teleflex USD 307.43M 21K Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026